Responses
Clinical/translational cancer immunotherapy
Original research
A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma
Compose a Response to This Article
Other responses
No responses have been published for this article.
